Pill for Gonorrhea? New Antibiotic Could Replace Injections
United States: New results from late-stage trial examinations reveal that gepotidacin demonstrates safety and efficacy for the treatment of gonorrhea, as published Monday in The Lancet study.
New Oral Antibiotic Could Redefine Gonorrhea Treatment
Scientists approved the FDA to authorize the use of gepotidacin for treating uncomplicated urinary tract infections in women and girls ages 12 and older in March 2023. This medicine blocks bacterial multiplication inside the human body, as reported by The Hills.
The approval of gepotidacin for gonorrhea treatment would establish its position as the most recent antibiotic for sexually transmitted infections beyond the 1990s.
Pharmaceutical company GSK produces gepotidacin, which has its brand name “Blujepa,” for distribution to the market.
The Centers for Disease Control and Prevention (CDC) shows that gonorrhea cases in the US reached their historic minimum in 2009 before starting a steady rise, which has slowed down beginning in 2021.
Urgency Grows as Gonorrhea Resistance Rises
Gonorrhea stands as the nation’s second most common sexually transmitted infection despite the fact that the Centers for Disease Control and Prevention reported 601,319 newly diagnosed cases in 2023.
Other sexually transmitted infections alongside gonorrhea demonstrate growing antibiotic resistance which makes their treatment increasingly difficult.
Patient care for gonorrhea treatment now involves a 500 mg injection of ceftriaxone as recommended by the CDC. The CDC issued new treatment guidance 2023 requiring medical providers to use increased drug amounts because of rising antibiotic resistance.
Justin Gill, who serves as both an urgent care nurse practitioner and president of the Washington State Nurses Association, reveals that gonorrhea treatment at his facility requires ceftriaxone, yet he has observed resistant cases of this infection.
“There are only a handful of antibiotics that are available as backup options,” he said. “The development of new antibiotics has been slow, but federal investment in new and emerging antibiotic options is necessary before resistant strains of gonorrhea expand further.”
Gonorrhea, when untreated, leads to medical complications, which result in infertility among men and women and raises the chance to acquire and transfer HIV per the CDC.
Gepotidacin, an oral antibiotic, shows promise against antibiotic-resistant gonorrhea, matching current treatments in efficacy. This could enhance patient experience and address rising resistance concerns. @thelancet @TheLancet https://t.co/1xqm1diKa6 https://t.co/jgisKRCxyg
— Medical Xpress (@medical_xpress) April 14, 2025
Promising Trial Results Show 92% Effectiveness
Medical trials involving 620 subjects demonstrated that gepotidacin achieved 92 percent effectiveness in fighting gonorrhea infections among double-daily drug users. The combination therapy of ceftriaxone with azithromycin succeeded in curing gonorrhea infections with 91 percent effectiveness, as reported by The Hills.
Researcher Stuart Ray of Johns Hopkins School of Medicine described the importance of such results as “exciting” during his assessment of the findings. The fact that patients can take the medication as pills contributes to its “attractive” features, according to Moore.
“In general, it’s very exciting to see a late-stage trial for a new antimicrobial for a thorny problem like gonorrhea,” he said. “I think it’s very exciting to see data and progression of an agent this far down the path.”
Less than 10 percent of the more than 600 trial participants were women, according to Ray.
“We have to be careful about making conclusions about subgroups that may have been somewhat underrepresented.”
About the Author
